RESOURCES

How much of your compound’s activity are your assays really detecting? Understanding how receptor density impacts pharmacological responses is critical for accurately characterizing compound activity & identifying candidates with the highest likelihood of therapeutic success. Review the latest GPCR white paper, “Functional ‘Volume Control’ in Cell Systems,” by GPCR expert Terry Kenakin, Ph.D., Professor of Pharmacology at the University of North Carolina School of Medicine, in collaboration with Eurofins DiscoverX^®. The white paper explores how tuning receptor density & system sensitivity can uncover hidden efficacies, improve characterization of agonists & antagonists, & provide more predictive pharmacology.

Caco-2 monolayers are widely employed in early drug discovery to estimate intestinal permeability; however, their drug-metabolizing enzyme profile does not accurately reflect that of the human intestine.

Intestinal mucus constitutes the first physiological barrier encountered by orally administered drugs, forming a hydrated, viscoelastic network that can substantially influence compound diffusion before epithelial absorption.

With over 15 years of experience in oncology research and drug discovery, partnering with global biopharma companies to advance translational research and accelerate preclinical drug development

Both a thyroid hormone receptor (THR)-beta agonist, resmetirom and a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide were recently approved for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.

Human epidermal growth factor receptor 2 (HER2) is a member of the human epidermal growth factor receptor tyrosine kinase family that regulates cell proliferation, survival, and differentiation.

Acute myeloid leukemia (AML) is the most common acute leukemia diagnosed in adults. DNA-hypomethylating agents (HMAs), such as decitabine and azacitidine, are widely used to treat AML and myelodysplastic syndromes (MDS).

Enhance Patient Safety. Reduce Clinical Attrition. Accelerate Regulatory Approval.

Accelerating the Development of Next-generation Therapeutics for Obesity | Product solutions guide (product list) for obesity therapeutics development. Combining comprehensive target coverage for key targets (GLP-1R, GIPR, GCGR, Amylin/Calcitonin, & more) with clinically proven technology platform and cell-based assay products to accelerate your path from concept to clinic by cutting months or even years from your development timeline.

Recombinant Protein Development, Biophysics, and Structural Biology for Molecular Glue Discovery and Optimization

Clinical attrition of drug candidates is frequently driven by unforeseen safety liabilities, which are often associated with off-target pharmacological interactions.

Secondary pharmacology is increasingly used to identify off-target activities with potential clinical safety relevance.